Seres Therapeutics Inc. (MCRB)

3.29
0.23 7.50
NASDAQ : Health Technology
Prev Close 3.06
Open 3.04
Day Low/High 3.04 / 3.23
52 Wk Low/High 2.02 / 9.00
Volume 38.66K
Avg Volume 373.30K
Exchange NASDAQ
Shares Outstanding 69.91M
Market Cap 215.33M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seres Therapeutics To Present At The Canaccord Genuity 39th Annual Growth Conference

Seres Therapeutics To Present At The Canaccord Genuity 39th Annual Growth Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at the Canaccord Genuity 39 th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.

Seres Therapeutics To Host Second Quarter 2019 Financial Results And Operational Progress Conference Call And Webcast On August 6, 2019

Seres Therapeutics To Host Second Quarter 2019 Financial Results And Operational Progress Conference Call And Webcast On August 6, 2019

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on August 6, 2019 at 8:00 a.

Seres Therapeutics Issues Statement Regarding U.S. Food And Drug Administration Safety Alert Related To Use Of Fecal Microbiota Transplantation

Seres Therapeutics Issues Statement Regarding U.S. Food And Drug Administration Safety Alert Related To Use Of Fecal Microbiota Transplantation

Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres") today provided a statement on a safety alert from the U.

Seres Therapeutics, Inc. Announces Pricing Of Public Offering Of Common Stock

Seres Therapeutics, Inc. Announces Pricing Of Public Offering Of Common Stock

Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres"), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced the...

Seres Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

Seres Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres"), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that...

Seres Therapeutics To Present At The Jefferies 2019 Healthcare Conference

Seres Therapeutics To Present At The Jefferies 2019 Healthcare Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY on Wednesday, June 5 th at 2:30 p.

Oversold Conditions For Seres Therapeutics (MCRB)

Oversold Conditions For Seres Therapeutics (MCRB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Seres Therapeutics Reports First Quarter Financial Results And Provides Clinical Pipeline Progress Update

Seres Therapeutics Reports First Quarter Financial Results And Provides Clinical Pipeline Progress Update

Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company") today reported first quarter 2019 financial results and provided business updates.

Seres Therapeutics To Host First Quarter 2019 Financial Results And Operational Progress Conference Call And Webcast On May 2, 2019

Seres Therapeutics To Host First Quarter 2019 Financial Results And Operational Progress Conference Call And Webcast On May 2, 2019

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.

MCRB Crosses Above Key Moving Average Level

MCRB Crosses Above Key Moving Average Level

In trading on Tuesday, shares of Seres Therapeutics Inc crossed above their 200 day moving average of $7.03, changing hands as high as $7.13 per share. Seres Therapeutics Inc shares are currently trading up about 2.6% on the day.

Seres Therapeutics Presents New Preclinical Data Supporting The Development Of SER-401 For Immuno-Oncology At The 2019 American Association For Cancer Research Annual Meeting

Seres Therapeutics Presents New Preclinical Data Supporting The Development Of SER-401 For Immuno-Oncology At The 2019 American Association For Cancer Research Annual Meeting

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (poster title "Leveraging gut microbiota networks to impact tumor immunotherapy") 1 will be...

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration With AstraZeneca

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration With AstraZeneca

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced a three-year research collaboration with AstraZeneca.

Seres Therapeutics Reports Fourth Quarter And Full Year Financial Results And Provides Operational Updates

Seres Therapeutics Reports Fourth Quarter And Full Year Financial Results And Provides Operational Updates

Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported fourth quarter and full year 2018 financial results and provided an operational update.

Seres Therapeutics To Present At Three Upcoming March Conferences

Seres Therapeutics To Present At Three Upcoming March Conferences

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences: Chardan's Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7 th at 8:10 a.

Seres Therapeutics To Host Fourth Quarter And Full Year 2018 Financial Results And Operational Progress Conference Call And Webcast On March 6, 2019

Seres Therapeutics To Host Fourth Quarter And Full Year 2018 Financial Results And Operational Progress Conference Call And Webcast On March 6, 2019

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.

Seres Therapeutics Announces Corporate Changes To Focus On Advancing Clinical Assets

Seres Therapeutics Announces Corporate Changes To Focus On Advancing Clinical Assets

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced certain corporate changes to focus resources on its highest priority, clinical-stage microbiome therapeutic candidates.

Seres Therapeutics Announces Chief Executive Officer Transition

Seres Therapeutics Announces Chief Executive Officer Transition

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Eric D.

Seres Therapeutics Announces Initiation Of SER-287 Phase 2B ECO-RESET Clinical Study For Ulcerative Colitis

Seres Therapeutics Announces Initiation Of SER-287 Phase 2B ECO-RESET Clinical Study For Ulcerative Colitis

Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis.

Seres Therapeutics Is Now Oversold (MCRB)

Seres Therapeutics Is Now Oversold (MCRB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Seres Therapeutics To Present At The Stifel 2018 Healthcare Conference

Seres Therapeutics To Present At The Stifel 2018 Healthcare Conference

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 th at 9:30 a.

Seres Therapeutics Reports Third Quarter Financial Results And Provides Operational Updates

Seres Therapeutics Reports Third Quarter Financial Results And Provides Operational Updates

Seres Therapeutics, Inc. (NASDAQ:MCRB) today reported third quarter 2018 financial results and provided an operational update.

Seres Therapeutics To Host Third Quarter 2018 Financial Results And Operational Progress Conference Call And Webcast On November 8, 2018

Seres Therapeutics To Host Third Quarter 2018 Financial Results And Operational Progress Conference Call And Webcast On November 8, 2018

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.

Seres Therapeutics Announces Appointment Of Kevin Horgan, M.D., As Chief Medical Officer

Seres Therapeutics Announces Appointment Of Kevin Horgan, M.D., As Chief Medical Officer

Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of Kevin Horgan, M.

Seres Therapeutics To Present New Data Supporting SER-109 Clinical Activity At IDWeek 2018

Seres Therapeutics To Present New Data Supporting SER-109 Clinical Activity At IDWeek 2018

Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced it will present new data for SER-109, a microbiome candidate in Phase 3 development, at the IDWeek 2018 conference being held from October 3-7 in San Francisco, CA.

Seres Therapeutics Strengthens Board Of Directors With Appointment Of Meryl Zausner, Experienced Biopharmaceutical Financial Leader

Seres Therapeutics Strengthens Board Of Directors With Appointment Of Meryl Zausner, Experienced Biopharmaceutical Financial Leader

Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of Directors.

Seres Therapeutics Reports Second Quarter Financial Results And Provides Operational Updates

Seres Therapeutics Reports Second Quarter Financial Results And Provides Operational Updates

Seres Therapeutics, Inc. (NASDAQ:MCRB) today reported second quarter 2018 financial results and provided an operational update.

Seres Therapeutics To Host Second Quarter 2018 Financial Results And Operational Progress Conference Call And Webcast On August 2, 2018

Seres Therapeutics To Host Second Quarter 2018 Financial Results And Operational Progress Conference Call And Webcast On August 2, 2018

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.